ASX Biotech Stocks

About this theme

Biotech short interest is priced off binary events. A clinical-stage company's value rests on trial readouts and regulatory decisions whose dates are public, so positions build ahead of them and clear immediately afterwards — the sharpest short-interest moves in this theme are calendar-driven rather than gradual. Between those dates the recurring bear case is dilution: companies without revenue fund trials by issuing stock, and a raise at a discount is the outcome a short is positioned for. Commercial-stage names attract a different argument about reimbursement decisions, competitor launches and the cost of building a sales force in the United States. The asymmetry is what makes this basket distinctive: an approval or a licensing deal can multiply a small-cap price overnight, so a crowded short in a thinly traded developer carries loss potential unlike anything in the mining or banking themes.

Short positions come from official ASIC short position reports (published with a T+4 trading-day delay) joined with daily price and volume data. The chart averages the constituents reporting in each week and shades the range between the least and most shorted of them; a member with no data that week is absent from the average rather than counted as zero.